Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Enveric Biosciences, Inc. issued up to 426,390 shares of warrant to certain institutional investors for $7.05 per share exercise price and $0.125 per share purchase price.
- Security
- warrant
- Shares
- up to 426,390 shares
- Purchaser
- certain institutional investors
- Consideration
- $7.05 per share exercise price and $0.125 per share purchase price
Exact text from the filing
(collectively, the “Existing Warrants”). Pursuant to the Inducement Letters, the Holders agreed to exercise for cash their Existing Warrants at a reduced exercise price of $7.05 per share and pay a purchase price of $0.125 per share in consideration for the Company’s agreement to issue in a private placement (x) new Series E Common Stock Purchase Warrants
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Enveric Biosciences, Inc. entered into Inducement Letters with certain institutional investors valued at aggregate gross proceeds of approximately $3.1 million (effective 2025-12-11).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors
- Value
- aggregate gross proceeds of approximately $3.1 million
- Effective
- 2025-12-11
Exact text from the filing
On December 11, 2025, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain institutional investors (the “Holders”) that held certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, respectively (collectively, the “Existing Warrants”).
View on SEC.gov